211 related articles for article (PubMed ID: 14630792)
1. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.
Cools J; Quentmeier H; Huntly BJ; Marynen P; Griffin JD; Drexler HG; Gilliland DG
Blood; 2004 Apr; 103(7):2802-5. PubMed ID: 14630792
[TBL] [Abstract][Full Text] [Related]
2. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU
Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.
Lierman E; Folens C; Stover EH; Mentens N; Van Miegroet H; Scheers W; Boogaerts M; Vandenberghe P; Marynen P; Cools J
Blood; 2006 Aug; 108(4):1374-6. PubMed ID: 16645167
[TBL] [Abstract][Full Text] [Related]
4. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.
Jovanovic JV; Score J; Waghorn K; Cilloni D; Gottardi E; Metzgeroth G; Erben P; Popp H; Walz C; Hochhaus A; Roche-Lestienne C; Preudhomme C; Solomon E; Apperley J; Rondoni M; Ottaviani E; Martinelli G; Brito-Babapulle F; Saglio G; Hehlmann R; Cross NC; Reiter A; Grimwade D
Blood; 2007 Jun; 109(11):4635-40. PubMed ID: 17299092
[TBL] [Abstract][Full Text] [Related]
5. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.
Vandenberghe P; Wlodarska I; Michaux L; Zachée P; Boogaerts M; Vanstraelen D; Herregods MC; Van Hoof A; Selleslag D; Roufosse F; Maerevoet M; Verhoef G; Cools J; Gilliland DG; Hagemeijer A; Marynen P
Leukemia; 2004 Apr; 18(4):734-42. PubMed ID: 14973504
[TBL] [Abstract][Full Text] [Related]
6. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia.
Cools J; Stover EH; Wlodarska I; Marynen P; Gilliland DG
Curr Opin Hematol; 2004 Jan; 11(1):51-7. PubMed ID: 14676627
[TBL] [Abstract][Full Text] [Related]
7. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
[TBL] [Abstract][Full Text] [Related]
8. [FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutant of PDGFRA gene: a case report and literature review].
Qu SQ; Wang Y; Sun XJ
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):159-61. PubMed ID: 23611226
[No Abstract] [Full Text] [Related]
9. Mechanism for the decrease in the FIP1L1-PDGFRalpha protein level in EoL-1 cells by histone deacetylase inhibitors.
Ishihara K; Kaneko M; Kitamura H; Takahashi A; Hong JJ; Seyama T; Iida K; Wada H; Hirasawa N; Ohuchi K
Int Arch Allergy Immunol; 2008; 146 Suppl 1():7-10. PubMed ID: 18504399
[TBL] [Abstract][Full Text] [Related]
10. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.
Klion AD; Robyn J; Maric I; Fu W; Schmid L; Lemery S; Noel P; Law MA; Hartsell M; Talar-Williams C; Fay MP; Dunbar CE; Nutman TB
Blood; 2007 Nov; 110(10):3552-6. PubMed ID: 17709602
[TBL] [Abstract][Full Text] [Related]
11. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A
Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979
[TBL] [Abstract][Full Text] [Related]
12. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
[TBL] [Abstract][Full Text] [Related]
13. FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia.
Cools J
Verh K Acad Geneeskd Belg; 2005; 67(3):169-76. PubMed ID: 16089297
[TBL] [Abstract][Full Text] [Related]
14. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.
Gotlib J; Cools J; Malone JM; Schrier SL; Gilliland DG; Coutré SE
Blood; 2004 Apr; 103(8):2879-91. PubMed ID: 15070659
[TBL] [Abstract][Full Text] [Related]
15. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.
Lierman E; Michaux L; Beullens E; Pierre P; Marynen P; Cools J; Vandenberghe P
Leukemia; 2009 May; 23(5):845-51. PubMed ID: 19212337
[TBL] [Abstract][Full Text] [Related]
16. Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity.
Arai A; Yan W; Wakabayashi S; Hayashi S; Inazawa J; Miura O
Int J Hematol; 2007 Oct; 86(3):233-7. PubMed ID: 17988989
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.
Shen Y; Ren X; Ding K; Zhang Z; Wang D; Pan J
Oncotarget; 2014 Nov; 5(21):10407-20. PubMed ID: 25431951
[TBL] [Abstract][Full Text] [Related]
18. Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder.
Ng HJ; Tan DC; Yiu RC; How GF
Leuk Res; 2008 Jan; 32(1):169-71. PubMed ID: 17544504
[TBL] [Abstract][Full Text] [Related]
19. FIP1L1-PDGFRA positive chronic eosinophilic leukaemia and associated central nervous system involvement.
Williams C; Kalra S; Nath U; Bown N; Wilson V; Wilkins BS; Neylon AJ
J Clin Pathol; 2008 May; 61(5):677-80. PubMed ID: 18256119
[TBL] [Abstract][Full Text] [Related]
20. Pure red cell aplasia associated with imatinib-treated FIP1L1-PDGFRA positive chronic eosinophilic leukemia.
Tanaka H; Iwato K; Asou H; Kimura A
Intern Med; 2010; 49(12):1195-200. PubMed ID: 20558942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]